Significant Ownership of Teoxane SA

Signature - Title
/s/ Patrice Calvayrac - Patrice Calvayrac/ Chief Financial Officer
Location
Geneva, Switzerland
Summary
This page shows a list of all the recent SCHEDULE 13D/G filings made by Teoxane SA.

Follow Filing Activity

Follow Teoxane SA and return when a new Schedule 13D/G filing changes the record on this page.

This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean. If you create an account from here, we will bring you back after verification.

Significant Ownership of Teoxane SA

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
RVNC Revance Therapeutics, Inc. Common Stock, par value $0.001 per share 6.2% $32,335,404 6,550,800 0% Teoxane SA 30 Jan 2025

Schedules 13D/G Reported by Teoxane SA:

Sym Target Class Ownership Change Current Shares Change Value Reporting name Form Report Period Filing Date
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .